Fig. 2
From: The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored
Microbiome-related therapeutic strategies for AD. Preliminary evidence from mouse and human studies suggests that probiotics/prebiotics, fecal matter transplant from healthy donors into AD patients, microbiome modifying drugs, and direct targeting of gut microbiome controlled neuroinflammatory pathways may potentially be disease modifying therapeutic strategies and may reduce amyloid, tau, and neurodegeneration